
Shares of drug developer Phio Pharmaceuticals PHIO.O rises 12.4% to $2.36 premarket
Brokerage H.C. Wainwright assumes coverage with "buy" rating; sets PT at $14
New PT represents a near seven-fold increase from the stock's last close
"We believe Phio is flying under the radar with investors, and we have a bullish outlook for the stock" - H.C. Wainwright
Says co's lead asset skin cancer therapy, PH-762, has already showed "impressive clinical activity and exhibited favorable safety in an early-stage study"
Brokerage says it believes remaining open to partnering opportunities is "an underappreciated position in current market conditions"
As of last close, stock up 16.7% YTD